Category:
Medical Studies
19th Annual Miami Brest Cancer Conference
What is the optimal local and systemic therapy for DCIS? Do all DCIS patients need radiation therapy? What is the optimal endocrine therapy for DCIS?
|
2001 |
Category:
Medical Studies
World Wide Breast Cancer Clinical Trial
Yorks leads worldwide cancer test
9,000 to take part in biggest research yet
by ALISON BELLAMY
WOMEN in Leeds are taking part in the world's largest drugs trial to treat breast cancer.
It comes as figures released today show the early forms of breast cancer are increasing.
But doctors say that is thanks to the success of their breast screening programme, which means more cases than ever before are being detected.
Now in an effort to save more lives St James's Hospital in Leeds is organising the world's largest drug and detection trial – they are looking for 9,000 volunteers worldwide – funded by Leeds-based Cancer Research UK.
|
2006/01/25 |
Category:
Medical Studies
Breast Ducts: A New Site for Cancer Treatment?
BALTIMORE, Jan. 25 (AScribe Newswire) -- Johns Hopkins Kimmel Cancer Center researchers are studying whether delivering chemotherapy drugs directly to breast "plumbing" might make treatment of early breast cancer easier on the patient and at least as good as surgery or radiation.
A report on successful tests of intraductal therapy in rats and mice published in the January 15 issue of Cancer Research has paved the way for one of the first preliminary clinical trials in women with breast cancer, currently under way in women with breast cancer scheduled for a mastectomy at Johns Hopkins.
|
2006/01/25 |
Category:
Medical Studies
DCIS as Predictor of Future Breast Disease: Presented at ASBD
SAN FRANCISCO, CA -- April 19, 2007 -- Researchers have found a link between ductal carcinoma in situ (DCIS) and increased risk of future invasive breast disease, according to data presented here at the 31st Annual Symposium of the American Society of Breast Disease (ASBD).
DCIS accounts for 20% to 30% of breast cancers. When treated appropriately, DCIS has been shown to have a high 10-year cancer specific survival (more than 97%). However, the risk of local recurrence following surgery and radiation for this condition is about 16% at 12 years. There are several factors that may predict the risk of tumour recurrence, including size of the tumour, margin width following resection, nuclear grade, and age of the patient at presentation.
|
2007/04 |
Category:
Medical Studies
MRI Helps Identify Tumours Hidden by Mammography: Presented at ASBD
SAN FRANCISCO, CA -- April 18, 2007 -- Researchers presented new diagnostic techniques in breast cancer screening at the 31st Annual Symposium of the American Society of Breast Disease (ASBD).
While mammography is the most commonly used screening method for breast cancer, according to cancer experts, magnetic resonance imaging (MRI) has also been shown to be a useful screening tool.
|
2007/04 |
Category:
Medical Studies
New Culture Technique Could Lead To Drug Discoveries
A novel cell culture technique for a noninvasive breast malignancy known as ductal carcinoma in situ (DCIS) could facilitate the discovery of new drugs to prevent DCIS recurrence or progression.
Gillian Farnie, Ph.D, of the University of Manchester in England, and colleagues developed a novel method to culture DCIS cells, and using this method, they examined the role of the epidermal growth factor receptor and Notch signaling pathways in the growth of DCIS. They found that both pathways were involved in self-renewal of DCIS cells; the former was necessary for DCIS growth, and the latter was important for cell survival.
|
2007/04 |
Category:
Miscellaneous
Susan G. Komen for the Cure Announces Nearly $82 Million in Grants; Significant Step in Goal to Inve
. . . Komen continues to fund leading-edge, investigator-initiated breast cancer research as a hallmark of its Research Grants and Awards Program. This year, the organization also added several new grant funding categories, including higher-dollar impact grants that fall under the category of Focused Areas of Study. Komen initially planned to fund up to $13 million worth of grants in four specific focus areas, including ductal carcinoma in situ (DCIS), experimental model systems, biomarker identification and validation, and environmental research methods. Strong response to the call for applications prompted Komen to make an additional infusion of up to $7 million, bringing the potential funding total for the inaugural year of its Focused Areas of Study category's existence to $20 million.
|
2007/04 |
Category:
Medical Studies
CancerBackup Clinical Trials
Six open trials as of June 6, 2007
|
2007/06 |
Category:
Medical Studies
Clinical Trials at National Cancer Institute
Objectives
1. Evaluate actuarial local in situ and invasive recurrence rates at 5 and 10 years after local excision in women with a favorable ductal carcinoma in situ (DCIS) prognosis.
2. Evaluate concordance between institutional pathologists and central review pathologists with respect to diagnosis and grading of DCIS.
3. Identify parameters that indicate increased or decreased risk of recurrence in the absence of irradiation.
4. Evaluate patterns of salvage of recurrence and rates of breast conservation.
5. Evaluate actuarial relapse-free, overall, and cause-specific survival at 5 and 10 years post DCIS excision.
|
2007/06 |
Category:
Definition & Diagnosis
Carcinoma in Situ
Ductal carcinoma in situ (DCIS) is the earliest possible clinical diagnosis of breast cancer and is frequently diagnosed with screening mammography that has detected small areas of calcification in the breast. Patients rarely suspect that they have breast cancer with this stage cancer. It is estimated that the average time to develop invasive breast cancer from DCIS is 5-8 years.
A variety of factors ultimately influence a patient's decision to receive treatment of cancer. The purpose of receiving cancer treatment may be to improve symptoms through local control of the cancer, increase a patient's chance of cure, or prolong a patient's survival. The potential benefits of receiving cancer treatment must be carefully balanced with the potential risks of receiving cancer treatment.
The following is a general overview of the treatment of DCIS. Circumstances unique to your situation and prognostic factors of your cancer may ultimately influence how these general treatment principles are applied. The information on this Web site is intended to help educate you about your treatment options and to facilitate a mutual or shared decision-making process with your treating cancer physician.
Most new treatments are developed in clinical trials. Clinical trials are studies that evaluate the effectiveness of new drugs or treatment strategies. The development of more effective cancer treatments requires that new and innovative therapies be evaluated with cancer patients. Participation in a clinical trial may offer access to better treatments and advance the existing knowledge about treatment of this cancer. Clinical trials are available for most stages of cancer. Patients who are interested in participating in a clinical trial should discuss the risks and benefits of clinical trials with their physician. To ensure that you are receiving the optimal treatment of your cancer, it is important to stay informed and follow the cancer news in order to learn about new treatments and the results of clinical trials.
DCIS can be thought of as a pre-cancerous or early stage growth of abnormal cells in the ducts of the breast. Historically, DCIS was an extremely uncommon finding in women and little attention was given to defining its optimal treatment. This is because DCIS can be cured almost 100% of the time with a surgical mastectomy. With the increased use of screening mammography, women are more likely to have cancer diagnosed at an earlier stage, and therefore, the number of women diagnosed with DCIS is increasing. If DCIS is untreated, approximately 30% of patients will develop invasive breast cancer an average of 10 years from the initial diagnosis.
|
|
Category:
Medical Studies
Clinical Trials: An Introduction
Clinical trials are studies that evaluate the effectiveness of new drugs or treatment strategies. The development of more effective cancer treatments requires that new and innovative therapies be evaluated with cancer patients. Each clinical trial is designed to find new or better ways to treat cancer patients. In oncology, clinical trials are especially important because, in the absence of high cure rates, nearly all therapeutic approaches are developmental in nature.
Currently, there are hundreds of ongoing clinical trials in the United States. Although clinical trials are an important component of cancer care and are crucial for improving cancer treatment, fewer than 5% of cancer patients currently participate in clinical trials because they are uninterested or unaware that they exist, have difficulty finding an appropriate clinical trial that may be of benefit to them, or are ineligible to participate in a clinical trial because of prior treatment interventions.
It is extremely important to decide whether or not to participate in a clinical trial before receiving any treatment from a physician. Once treatment has been initiated, this almost always excludes patients from participating in a clinical trial designed for patients in their circumstance. To learn more about clinical trials, please click on any of the subcategories.
|
|
Category:
Miscellaneous
Living Beyond Breast Cancer
DCIS, LCIS Diagnosis May Put Some Women at Higher Risk for Invasive Breast Cancer
LCIS may put women at higher risk for developing invasive breast cancers than previously believed, a new study says. Women with DCIS who are under age 50 or African-American or Latina are at higher risk for developing advanced-stage disease, the study showed. Read more ...
Breast Density May Indicate Risk for Invasive Breast Cancer After DCIS
High breast density may be a risk factor for invasive breast cancer in the opposite breast for women with DCIS, results of a prospective study indicate. Read more ...
DCIS and LCIS Are Focus of April Teleconference
Understand a diagnosis of DCIS or LCIS and gain practical tips to lessen your risk of developing invasive disease. Read more ...
|
2007/06 |
Category:
Medical Studies
MRI Can Detect Breast Disease Missed By Mammography, Study Shows
Researchers have found that mammography coupled with magnetic resonance imaging (MRI) is extremely sensitive in the detection of ductal carcinoma in situ (DCIS). DCIS, or early stage breast carcinoma, is a pre-invasive malignancy and MRI may help identify this type of disease, which may not be visible on a mammogram. This study is published in The Breast Journal.
The study examined the medical records of women diagnosed with DCIS, aged 34 to 79 years, who underwent MRI and mammographic examinations during a period of approximately two years. The results revealed 39 sites of pure DCIS in 33 breasts of 32 women. In each of these women, both MRI and mammograms were performed prior to surgery. Of the 33 breasts involved, DCIS was detected by MRI alone in 64 percent, and detected by mammography alone in only 3 percent. MRI and mammography together detected DCIS in 24 percent of breasts; in 9%, DCIS was found at mastectomy but the mammogram and MRI were negative.
|
2006/02 |
Category:
Miscellaneous
Annie Appleseed Project
Many articles on breast cancer...and...specific articles on DCIS
Some examples:
Results of a study very low mortality with DCIS/other DCIS info
Lumpectomy=Mastectomy for DCIS
Salvage Treatment
7th International Conference on Adjuvant Therapy
Risk Factors Subseq Invasive Bca
Management of DCIS
Tumor Markers Correlate w/Grade
Current Treatment of DCIS
Value of Lumpectomy Margin Assess
LCIS
DCIS Diagnosed 20% of Time
Mucinous Cancers
Metaplastic Bca: Path/Outcomes
Squamous Cell Ca of the Breast
Smoking & Radiation Therapy
DCIS Issues - SABCS 2006
|
2007/07 |
Category:
Medical Studies
Importance of HER-2/Neu Positivity as Predictor of Outcome in DCIS Remains Controversial
SAN ANTONIO-HER-2/neu testing in DCIS is controversial: Does this test provide useful information? Is HER-2 positivity a predictor of recurrence? Is the test worth the extra cost? Two posters at the San Antonio Breast Cancer Study presented studies that came to different conclusions.
The first suggested that HER-2/neu overexpression was a predictor of invasive recurrence, and the second study said it was not predictive of outcome.
On closer inspection, however, the studies had important differences, suggesting that in fact, HER-2/neu positivity may be associated with recurrence of invasive cancer. The controversy will not be resolved until more definitive studies are conducted.
|
2007/04 |
Category:
Medical Studies
Importance of HER-2/Neu Positivity as Predictor of Outcome in DCIS Remains Controversial
SAN ANTONIO-HER-2/neu testing in DCIS is controversial: Does this test provide useful information? Is HER-2 positivity a predictor of recurrence? Is the test worth the extra cost? Two posters at the San Antonio Breast Cancer Study presented studies that came to different conclusions.
The first suggested that HER-2/neu overexpression was a predictor of invasive recurrence, and the second study said it was not predictive of outcome.
On closer inspection, however, the studies had important differences, suggesting that in fact, HER-2/neu positivity may be associated with recurrence of invasive cancer. The controversy will not be resolved until more definitive studies are conducted.
At this time, HER-2/neu testing should not be considered part of routine care for ductal carcinoma in situ, said Henry Kuerer, MD, PhD, Director of Breast Surgical Oncology Training at the University of Texas M. D. Anderson Cancer Center.
DCIS is currently overtreated, he said, and he and his colleagues are looking at DCIS in a prevention setting-that is, we perform surgery, radiation, and administer tamoxifen only to prevent the development of invasive cancer, he said. The jury is still out on whether or not HER-2/neu overexpression is associated with an independent increased chance of local recurrence with invasive breast cancer following a diagnosis of DCIS.
|
2007/04 |
Category:
Miscellaneous
New Treatments for Breast Cancer
The optimal management of ductal carcinoma in situ (DCIS) of the breast is one of the greatest challenges in breast disease faced by clinicians today. Ductal carcinoma in situ comprises 20% to 40% of all mammogram-directed biopsies. The National Cancer Database reports that DCIS comprised 7% of all newly diagnosed breast cancers in 1985.
|
|
Category:
Definition & Diagnosis
Almac Diagnostics Announces Pioneering Genetic Research On Ductal Carcinoma In Situ (DCIS) Using Bre
Almac Diagnostics has announced a major study analysing ductal carcinoma in situ tissue samples using its novel Breast Cancer DSA™ microarray. DSA™ research tools focus on the transcriptome of an individual disease, in this case breast cancer, and contain significant additional data, relevant to the disease of interest that is not available on other generic microarrays. The study will be conducted in collaboration with Prof Adrian Harris, Cancer Research UK and Professor of Medical Oncology at the University of Oxford.
|
2007/08 |
Category:
Miscellaneous
Clinical Trials by Cancer Site
Breast cancer is the most commonly diagnosed type of cancer in women. It is estimated that in 2006, there will be 212,920 new cases of invasive breast cancer in women and 1,720 cases in men. The risk factors for breast cancer include age, high breast tissue density, confirmed hyperplasia, long menstrual cycles, use of oral contraceptives, having first child after the age of 30, never having children, inherited genetic mutations (BRCA 1 and BRCA 2), personal or family history of breast cancer, and having received high-dose radiation therapy to the chest for medical treatment.
Treatment options for breast cancer may vary depending on tumor size, stage of the disease, whether the cancer is newly diagnosed or recurrent/refractory, other medical conditions, and the patient's treatment preference, and should be discussed with the patient's physician.
|
2008/01 |
Category:
Definition & Diagnosis
Ductal Carcinoma in Situ of the Breast
Ductal carcinoma in situ (DCIS) of the breast is an early, localized cluster of cancer cells that start in the milk passage ducts of the breast but have not penetrated the duct walls into the surrounding tissue. The term "in situ" refers to a tumor that has not spread beyond the place where it originally developed.
Ductal carcinoma in situ of the breast is sometimes described as "pre-cancerous", "pre-invasive", "non-invasive", or "intraductal carcinoma". If left untreated, however, DCIS may progress to ‘true’ breast cancer by spreading into and invading the surrounding healthy breast tissue. Because doctors cannot predict with any degree of certainty whether DCIS will develop into invasive breast cancer, early diagnosis and treatment is crucial. With appropriate treatment, the prognosis (outlook) for women with ductal carcinoma in situ of the breast is excellent.
|
2008/01 |